|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.410 USD | +5.76% |
|
-3.08% | +5.50% |
| 12-23 | Precigen Insider Sold Shares Worth $7,942,150, According to a Recent SEC Filing | MT |
| 11-24 | Precigen Insider Sold Shares Worth $12,291,748, According to a Recent SEC Filing | MT |
| Capitalization | 1.56B 1.34B 1.25B 1.16B 2.16B 141B 2.33B 14.33B 5.64B 67.38B 5.85B 5.73B 247B | P/E ratio 2025 * |
-5.03x | P/E ratio 2026 * | -24.5x |
|---|---|---|---|---|---|
| Enterprise value | 1.55B 1.33B 1.24B 1.15B 2.15B 140B 2.32B 14.25B 5.61B 67B 5.82B 5.7B 246B | EV / Sales 2025 * |
115x | EV / Sales 2026 * | 15.8x |
| Free-Float |
90.08% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Precigen, Inc.
More recommendations
More press releases
| 1 day | +5.76% | ||
| 1 week | -3.08% | ||
| Current month | +5.50% | ||
| 1 month | +19.51% | ||
| 3 months | +37.38% | ||
| 6 months | +140.98% | ||
| Current year | +5.50% |
| 1 week | 3.93 |  | 4.82 |
| 1 month | 3.64 | | 4.95 |
| Current year | 3.93 | | 4.95 |
| 1 year | 1.07 | | 5.22 |
| 3 years | 0.65 | | 5.22 |
| 5 years | 0.65 | | 9.89 |
| 10 years | 0.65 | | 40.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Harry Thomasian
DFI | Director of Finance/CFO | 64 | 30/09/2021 |
Amy Lankford
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Randal Kirk
CHM | Chairman | 72 | 31/01/2008 |
Cesar Alvarez
BRD | Director/Board Member | 78 | 31/01/2008 |
Jeffrey Kindler
BRD | Director/Board Member | 70 | 27/11/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.76% | -3.08% | +312.15% | +119.40% | 1.48B | |
| -0.36% | +0.87% | +34.59% | +196.80% | 964B | |
| +2.29% | +6.72% | +51.28% | +26.02% | 515B | |
| +0.52% | -0.91% | +25.55% | +44.46% | 390B | |
| +0.94% | +4.30% | +29.90% | +17.96% | 363B | |
| +2.41% | +2.19% | +32.56% | +23.08% | 292B | |
| +2.13% | +4.07% | +27.83% | +37.35% | 272B | |
| +2.54% | +1.97% | +9.93% | -1.10% | 269B | |
| -1.32% | +3.90% | -38.31% | -19.23% | 265B | |
| +1.44% | -0.36% | +21.76% | +21.07% | 175B | |
| Average | +1.51% | -0.19% | +50.72% | +46.58% | 350.65B | |
| Weighted average by Cap. | +0.75% | +0.31% | +26.93% | +69.14% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.53M 11.61M 10.81M 10.06M 18.77M 1.22B 20.24M 124M 48.89M 584M 50.74M 49.7M 2.14B | 98.61M 84.62M 78.79M 73.32M 137M 8.9B 147M 906M 356M 4.26B 370M 362M 15.6B |
| Net income | -266M -228M -212M -198M -369M -23.98B -397M -2.44B -960M -11.47B -996M -976M -42.04B | -53.52M -45.92M -42.76M -39.79M -74.25M -4.83B -80.05M -492M -193M -2.31B -201M -197M -8.47B |
| Net Debt | -8.9M -7.64M -7.11M -6.62M -12.35M -803M -13.31M -81.75M -32.16M -384M -33.38M -32.69M -1.41B | - |
More financial data
* Estimated data
Employees
143
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/01/26 | 4.410 $ | +5.76% | 3,614,375 |
| 13/01/26 | 4.170 $ | +0.85% | 3,414,529 |
| 12/01/26 | 4.135 $ | -9.91% | 5,971,957 |
| 09/01/26 | 4.590 $ | -0.43% | 3,534,946 |
| 08/01/26 | 4.610 $ | -4.95% | 3,862,178 |
Delayed Quote Nasdaq, January 14, 2026 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.410USD
Average target price
8.500USD
Spread / Average Target
+92.74%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PGEN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition